Trials / Conditions / Clostridium Difficile Infection Recurrence

Clostridium Difficile Infection Recurrence

15 registered clinical trials studyying Clostridium Difficile Infection Recurrence — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection NCT07513285	Acurx Pharmaceuticals Inc.	Phase 2
Recruiting	Real-World Study on Fecal Microbiota Transplantation: Long-Term Effectiveness and Safety Statistics NCT07261826	Chen QiYi	—
Recruiting	VE303 for Prevention of Recurrent Clostridioides Difficile Infection NCT06237452	Vedanta Biosciences, Inc.	Phase 3
Withdrawn	Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections NCT05606159	Novozymes A/S	N/A
Completed	A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Co NCT05831189	Ferring Pharmaceuticals	Phase 3
Terminated	Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients NCT03617445	University of Wisconsin, Madison	Phase 2
Unknown	Bezlotoxumab Efficacy and Tolerability in Cancer Patient NCT04415918	The Cooper Health System	Phase 4
Completed	A Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI) NCT04891965	Adiso Therapeutics	Phase 1
Completed	Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection NCT04317963	University of Illinois at Chicago	—
Terminated	Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI) NCT04000555	University of South Florida	Phase 4
Completed	Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clo NCT03880539	University of Kansas Medical Center	Phase 4
Completed	Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection NCT03788434	Vedanta Biosciences, Inc.	Phase 2
Terminated	Treatment for Clostridium-difficile Infection With IMM529 NCT03065374	Immuron Ltd.	Phase 1 / Phase 2
Completed	Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent NCT03110133	Finch Research and Development LLC.	Phase 2
Recruiting	Outcomes and Data Collection for Fecal Microbiota Transplantation for the Treatment of Recurrent Clostridium D NCT03562741	Krunal Patel	N/A